Carl Bishop
Adult Health · Youngstown, OHNPI 1285937664
Payments from drug & device makers
Across 73 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$453
- AstraZeneca$246
- Otsuka America Pharmaceutical, Inc.$241
- Alkermes, Inc.$134
- Gilead$123
- Bayer$106
- plus $583 from 14 others
What the payments were for
- Food & beverage$1,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $453 |
| AstraZeneca(2 entities) | 2 | $246 |
| Otsuka America Pharmaceutical, Inc. | 9 | $241 |
| Alkermes, Inc. | 7 | $134 |
| Gilead | 1 | $123 |
| Bayer | 1 | $106 |
| Teva Pharmaceuticals USA, Inc. | 1 | $72 |
| Lundbeck LLC | 4 | $63 |
| Exact Sciences | 1 | $60 |
| Neurocrine Biosciences, Inc. | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Noven Therapeutics, LLC | 3 | $43 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Scilex Pharmaceuticals Inc. | 2 | $32 |
| Evoke Pharma, Inc. | 2 | $27 |
| Halozyme Inc | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,886 in reported general payments places this provider in the 80th percentile of 1,184 adult health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 15 | $19,054 |
| JardianceEmpagliflozin | 24 | $16,042 |
| EliquisApixaban | 14 | $9,828 |
| FarxigaDapagliflozin Propanediol | 12 | $7,031 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,180 |
| Pregabalin | 28 | $1,049 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $972 |
| Omeprazole | 44 | $942 |
| Pioglitazone Hcl | 40 | $713 |
| Ropinirole Hcl | 20 | $532 |
| Atorvastatin Calcium | 75 | $476 |
| Gabapentin | 33 | $357 |
| Rosuvastatin Calcium | 39 | $343 |
| Quetiapine Fumarate | 24 | $332 |
| Lisinopril | 52 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $14 | $19,05415 claims |
| AstraZenecaFarxiga | $246 | $7,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,184 adult health providers in Ohio.
Other adult health in Youngstown
- Jesse McClainYoungstown$79K
- Frances ClarkYoungstown$18K
- Deborah NicholsYoungstown$8K
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Margaret TiktinCleveland$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.